09.12.2016
Carl Zeiss Meditec AG DE0005313704
DGAP-News: Carl Zeiss Meditec AG continues its growth trend
DGAP-News: Carl Zeiss Meditec AG / Key word(s): Final Results
Carl Zeiss Meditec AG continues its growth trend
09.12.2016 / 07:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Positive revenue and earnings trend - further growth in recurring revenue
JENA, 9 December 2016
Carl Zeiss Meditec AG has brought financial year 2015/16 to a successful
close with further growth: Revenue increased by 4.6 percent (adjusted for
currency effects: 2.7 percent) to EUR1,088.4m. Earnings before interest and
taxes (EBIT) rose to EUR154.3m (prior year: EUR130.6m). The EBIT margin
increased to 14.2 percent (prior year: 12.6 percent). Earnings per share
reached EUR1.21 (prior year: EUR0.77).
Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG looks back on
the past fiscal year with satisfaction: "We have achieved profitable growth
and met our forecast revenue range of EUR1,080 - EUR1,120m. We have also
gained additional market share, particularly in Ophthalmology. The trend in
recurring revenue is also positive - as much as 32% of our business is
attributable to consumables for cataract and refractive surgery, service
revenue and other recurring sources of revenue. The new organizational
structure announced in July 2016 will help us to offer our customers an
even better service and to seize additional opportunities for growth."
Strongest growth in Ophthalmic Systems SBU
Both Ophthalmology business units achieved growth: revenue in the
Ophthalmic Systems SBU (OPH) increased by 7.5 percent in the fiscal year,
to EUR421.2m, compared with EUR392.0m in the same period of the prior year.
Adjusted for currency effects, revenue increased by 5.2 percent. The
business with laser systems for refractive vision correction developed
particularly well. The Surgical Ophthalmology SBU (SUR) increased its
revenue by 4.3 percent (adjusted for currency effects: 2.9 percent) to
EUR370.7m (prior year: EUR355.3m). Significant increases were once again
achieved by intraocular lenses for treating cataracts. Under the new SBU
structure, the combined SBU Ophthalmic Devices would have grown revenue to
EUR791.9m - an increase of 6.0 percent (4.1 percent adjusted for currency
effects).
Revenue growth in the Microsurgery SBU was 1.3 percent and was boosted by
positive currency effects. Revenue from surgical microscopes and
visualization solutions climbed to EUR296.5m, compared with EUR292.8m in
the prior year. The development of business in the Japanese market was
particularly restrained. Adjusted for currency effects, revenue was down by
-0.9%, thus remaining slightly below the level of a year ago.
Asia/Pacific becomes largest reporting region
After another strong performance by Asia/Pacific, this reporting region has
become the largest segment for the first time. At EUR381.7m, revenue was
significantly higher than the prior-year figure of EUR319.4m - an increase
of 19.5 percent. Adjusted for currency effects, this growth would still
have amounted to 15.5 percent. A large part of this growth is attributable
to the Chinese market, as well as Southeast Asia and South Korea.
Revenue in the EMEA region declined slightly, by 1.7 percent to EUR352.7m
(prior year: EUR358.8m). Germany, France and the United Kingdom made good
contributions to revenue Business in Southern Europe and the Middle East
declined.
Revenue in the Americas region decreased by 2.2 percent to EUR354.0m (prior
year: EUR361.9m). The strength of the US dollar had a positive effect in
this region.
The persistently high competitive pressure had a curbing effect,
particularly in the area of ophthalmic diagnostics. Adjusted for currency
effects, a decline of -4.9 percent was recorded compared with the prior
year.
Earnings per share (EPS) increased significantly year-on-year, to EUR1.21
(prior year: EUR0.77). The increase in operating profit contributed to this
- the prior year was also affected significantly by extraordinary expenses
arising from a financial interest.
Carl Zeiss Meditec AG has set itself the target to continue growing at
least the same rate as the underlying market in fiscal year 2016/17. The
EBIT margin is expected to continue to move within the range also forecast
for the medium term, of 13-15%.
Revenue by strategic business unit
Figures in EURm 12 Months 12 Months Change Change 2015/16 2014/15 compared to compared to prior year prior year (adjusted for currency effects) Ophthalmic 791.9 747.2 +6.0% +4.1% Devices - thereof 421.2 392.0 +7.5% +5.2% Ophthalmic Systems - thereof 370.7 355.3 +4.3% +2.9% Surgical Ophthalmology Microsurgery 296.5 292.8 +1.3% -0.9% Total 1,088.4 1,040.1 +4.6% +2.7%Revenue by region Figures in 12 Months 12 Months Change Change EURm 2015/16 2014/15 compared to compared to prior year prior year (adjusted for currency effects) EMEA 352.7 358.8 -1.7% -1.3% Americas 354.0 361.9 -2.2% -4.9% APAC 381.7 319.4 +19.5% +15.5% Total 1,088.4 1,040.1 +4.6% +2.7%Contact for media and investors Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel. +49 (0)3641 220 116 E-mail: [email protected] www.zeiss.com/presse Brief profile Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application- oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 2,900 employees worldwide, the Group generated revenue of EUR 1,088 million in financial year 2015/16 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading companies in the optical and optoelectronic industries. For more information visit our website at: www.zeiss.com/meditec-ag/ --------------------------------------------------------------------------- 09.12.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Carl Zeiss Meditec AG Göschwitzer Str. 51-52 07745 Jena Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: [email protected],[email protected] Internet: www.meditec.zeiss.de ISIN: DE0005313704 WKN: 531370 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 528213 09.12.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Carl Zeiss Meditec AG ISIN: DE0005313704 können Sie bei EQS abrufen
Medtech , 531370 , AFX , XETR:AFX